Clinical trialNCT06228053RecruitingPhase 2Interventional

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

SponsorSyntrix Biosystems, Inc.Enrollment53Metastatic Castration-resistant Prostate Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Syntrix Biosystems
Syntrix Biosystems, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California, Los Angeles
Los Angeles, California, United States
Adam E. Singer, MD, PhD
Recruiting
University of California, San Francisco
San Francisco, California, United States
Kelly Fitzgerald, MD
Recruiting
University of Michigan
Ann Arbor, Michigan, United States
Zachery R. Reichert, MD, PhD
Recruiting
University of Minnesota
Minneapolis, Minnesota, United States
Not, yet, recruiting
Duke University
Durham, North Carolina, United States
Andrew J. Armstrong, MD, ScM, FACP
Recruiting
University of Wisconsin
Madison, Wisconsin, United States
Douglas G. McNeel, MD, PhD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Enzalutamide →SX-682

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Nov 2024
Primary completion: 30 Jun 2027
Completion: 30 Jun 2028
Last update posted: 2 Jun 2026
Registered enrollment: 53
Registry id: NCT06228053

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.